Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. T…
Biotechnology
US, Waltham [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -44.66 | -120.78 | -83.49 | |
| Graham Fair Price | -0.03 | 5.13 | 5.14 | |
| PEG | 94.93 | 1.06 | 0.54 | |
| Price/Book | -26.20 | 27.53 | 37.31 | |
| Price/Cash Flow | 25.63 | -55.09 | -74.07 | |
| Prices/Earnings | -34.91 | -27.63 | -20.48 | |
| Price/Sales | -14.06 | 42.60 | 49.58 | |
| Price/FCF | 25.63 | -55.09 | -74.07 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 1.87 | 0.88 | 0.86 | |
| Operating Margin | 37.60 | -0.36 | -0.58 | |
| ROA | 28.90 | -0.08 | -0.11 | |
| ROE | -0.46 | -0.25 | 45.30 | |
| ROIC | -0.29 | -0.09 | 69.02 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 2.88 | 0.01 | 23274.39 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.43 | 0.27 | -38.30 | |
| EPS QOQ | 0.38 | 0.26 | -30.79 | |
| FCF QOQ | 0.42 | -0.36 | -14.35 | |
| Revenue QOQ | 0.48 | 0.18 | -62.75 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Bad
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 661.54 | 702.83 | 6.24 | |
| Days Sales Outstanding (DSO) | 126.93 | 139.88 | 10.20 | |
| Inventory Turnover | 0.14 | 0.13 | -5.87 | |
| Debt/Capitalization | 0.34 | 0.61 | 80.95 | |
| Quick Ratio | 2.27 | 2.80 | 23.05 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 1.60 | 2.17 | 35.17 | |
| Cash | 2.94 | 2.72 | -7.49 | |
| Capex | < 0.005 | < 0.005 | -204.09 | |
| Free Cash Flow | -0.81 | -1.08 | -34.13 | |
| Revenue | 1.21 | 1.40 | 16.08 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad